Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Edaravone Dexborneol for Post-Stroke Epilepsy (EDEN-PSE)

20 мая 2026 г. обновлено: First Affiliated Hospital of Wenzhou Medical University

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study of Edaravone Dexborneol Sublingual Tablets for the Prevention of Post-Stroke Epilepsy

This is a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial designed to evaluate the efficacy and safety of Edaravone Dexborneol sublingual tablets in preventing late-onset epilepsy in patients with acute ischemic stroke at high risk.

Eligible participants are adults aged 18-80 years with a confirmed diagnosis of acute ischemic stroke by clinical and imaging criteria (MRI or CT), enrolled within 48 hours of stroke onset. High risk for post-stroke epilepsy is defined as a SeLECT-EEG score ≥7. Patients must have no prior history of epilepsy or other central nervous system disorders associated with seizures. Key exclusion criteria include prior seizures before enrollment, recent stroke within the past 12 months, severe renal or hepatic dysfunction, significant cardiac insufficiency, drug hypersensitivity, pregnancy or lactation, and other conditions deemed unsuitable by investigators.

A total of approximately 160 participants will be randomized in a 1:1 ratio to receive either Edaravone Dexborneol sublingual tablets or matching placebo.

The primary endpoint is a composite outcome assessed within 2 years, defined as the occurrence of either: (1) definite clinical epileptic seizures, or (2) new-onset or worsening epileptiform EEG abnormalities (including IEDs, PDs, LRDAs) or electrographic seizures.

Secondary endpoints include: incidence of individual components of the primary outcome; time to first seizure; characteristics, severity, and frequency of seizures; longitudinal changes and resolution rate of epileptiform EEG activity; cognitive function assessed by MoCA and MMSE; neurological outcomes evaluated by mRS and NIHSS; quality of life and functional independence measured by SSQOL and Barthel Index; recurrence of stroke and all-cause mortality; changes in inflammatory biomarkers (TNF-α, IL-1β, COX-2, iNOS); and safety outcomes including treatment-emergent adverse events, serious adverse events, laboratory abnormalities, and treatment discontinuation due to adverse events.

All efficacy and safety outcomes will be independently reviewed by a blinded adjudication committee. Statistical analyses will include chi-square or Fisher's exact tests for categorical outcomes, Kaplan-Meier survival analysis with log-rank tests for time-to-event data, and Cox proportional hazards models to adjust for potential confounders.

The study period is planned from June 2026 to June 2030.

Обзор исследования

Статус

Еще не набирают

Условия

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Оцененный)

160

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Xinshi Wang
  • Номер телефона: +8613757897051
  • Электронная почта: wangxinshi@wmu.edu.cn

Места учебы

  • Китай
    • Zhejiang
      • Wenzhou, Zhejiang, Китай, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
        • Контакт:
          • Xinshi Wang
          • Номер телефона: 8613757897051
          • Электронная почта: wangxinshi@wmu.edu.cn
        • Контакт:

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

  • Взрослый
  • Пожилой взрослый

Принимает здоровых добровольцев

Нет

Описание

Inclusion criteria: 1. Adults aged 18 to 80 years, of either sex.

2. Diagnosis of acute ischemic stroke confirmed by clinical presentation and neuroimaging (MRI or CT).

3. Time from stroke onset to screening/randomization ≤48 hours.

4. High risk of post-stroke epilepsy, defined as a SeLECT-EEG score ≥7, including: stroke severity (Se, 0-2 points), large-artery atherosclerosis etiology (L, 0-1 point), cortical involvement (C, 0-2 points), middle cerebral artery territory infarction (T, 0-1 point), and EEG findings (EEG, 0-2 points).

5. No prior history of epilepsy before the index stroke, and no history of other central nervous system disorders (e.g., traumatic brain injury, brain tumor) associated with seizures.

6. Conscious at enrollment or with recovered consciousness after treatment, and able to cooperate with sublingual medication administration and follow-up assessments.

7. Provision of written informed consent by the patient or a legally authorized representative.

Exclusion criteria: 1. History of epilepsy or occurrence of any seizure prior to screening.

2. History of ischemic or hemorrhagic stroke within 12 months prior to the index stroke.

3. Large cerebral infarction with severe intracranial hypertension on imaging after stroke, with limited life expectancy or inability to complete follow-up.

4. Severe renal impairment (significantly reduced eGFR according to contraindications of edaravone dexborneol) or a history of edaravone-related renal injury.

5. Severe hepatic dysfunction (ALT or AST >3 times the upper limit of normal) or severe heart failure (New York Heart Association class III-IV) that may preclude tolerance to the study drug.

6. Known hypersensitivity to edaravone or borneol, or a history of severe drug allergy.

7. Pregnant or breastfeeding women; women of childbearing potential unwilling to use effective contraception.

8. Presence of other serious diseases (e.g., advanced malignancy) that may affect survival or study compliance.

9. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Профилактика
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Edaravone Dexborneol group
Participants in the experimental group will receive edaravone dexborneol sublingual tablets in addition to standard stroke therapy. Each tablet contains edaravone 30 mg and borneol 6 mg. The drug will be administered as one tablet sublingually twice daily, with an interval of at least 6 hours between doses. Treatment will be initiated within 48 hours after stroke onset and continued for 3 months.
Лекарство: Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.
In the experimental group, patients received edaravone dexborneol sublingual tablets in addition to standard stroke therapy. Each tablet contained edaravone 30 mg plus borneol 6 mg, administered as one tablet sublingually twice daily (with an interval of ≥6 hours between doses). Treatment was initiated as early as possible within 48 hours after stroke onset and continued for consecutive three months.
Плацебо Компаратор: Control group
Participants in the control group will receive matching placebo sublingual tablets with identical appearance, dosage form, and odor to the experimental drug. The administration method, dosing frequency, and treatment duration will be the same as in the experimental group. Both groups will receive standard stroke secondary prevention and rehabilitation therapy, without additional antiepileptic medications.
Лекарство: Placebo
In the control group, patients received placebo sublingual tablets identical in appearance, formulation, and odor to the investigational product (edaravone 0 mg plus borneol 60 μg, with trace borneol added to ensure odor matching). Administration was initiated within 48 hours of stroke onset, at a regimen of one tablet sublingually twice daily (≥6-hour interval between doses), continued for consecutive three months.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Proportion of participants with composite seizure-related events
Временное ограничение: Up to 24 months
Composite seizure-related events are defined as the occurrence of any of the following during follow-up: (1) clinical epileptic seizures occurring more than 7 days after stroke onset; (2) newly developed or worsening epileptiform activity on electroencephalography (EEG), including interictal epileptiform discharges (IEDs), periodic discharges (PDs), or lateralized rhythmic delta activity (LRDA); or (3) electrographic seizures.
Up to 24 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Number of participants with late-onset clinical seizures
Временное ограничение: Up to 24 months
Late-onset seizures are defined as clinical epileptic seizures occurring more than 7 days after stroke onset. The proportion of participants experiencing at least one seizure during follow-up will be recorded.
Up to 24 months
Proportion of participants with new or worsening epileptiform EEG abnormalities
Временное ограничение: Up to 24 months
Epileptiform EEG abnormalities include interictal epileptiform discharges (IEDs), periodic discharges (PDs), and lateralized rhythmic delta activity (LRDA). New abnormalities are defined as findings not present on baseline EEG. Worsening is defined as progression of pre-existing abnormalities compared with baseline, including increased frequency, transition to a continuous pattern, or expansion in spatial distribution.
Up to 24 months
Time to first late-onset clinical seizure
Временное ограничение: Up to 24 months
Time from stroke onset to the first occurrence of a late-onset clinical seizure, measured in days.
Up to 24 months
Proportion of participants with electrographic seizures without clinical manifestations
Временное ограничение: Up to 24 months
Electrographic seizures without clinical manifestations are defined as seizure activity detected on electroencephalography (EEG) without corresponding observable clinical symptoms. Participants will be counted as having an event if one or more such events are detected during follow-up.
Up to 24 months
Proportion of participants with resolution of epileptiform EEG activity
Временное ограничение: At 3, 6, 12, 18, and 24 months
Among participants with epileptiform EEG activity at baseline, the proportion achieving resolution (conversion to normal EEG without epileptiform discharges) will be assessed at each follow-up visit.
At 3, 6, 12, 18, and 24 months
Number of seizure episodes per participant
Временное ограничение: Up to 24 months
Total number of seizure episodes per participant during the 24-month follow-up period will be recorded. Median seizure frequency will be compared between groups.
Up to 24 months
Proportion of participants with severe seizure outcomes
Временное ограничение: Up to 24 months
Severe seizure outcomes include progression to status epilepticus or generalized tonic-clonic seizures. The distribution of seizure severity will be recorded.
Up to 24 months
Change in Montreal Cognitive Assessment (MoCA) score from baseline
Временное ограничение: Baseline, 3, 6, 12, 18, and 24 months
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA; total score range 0-30, higher scores indicate better cognitive function). Changes in score from baseline will be evaluated at each follow-up visit.
Baseline, 3, 6, 12, 18, and 24 months
Change in Mini-Mental State Examination (MMSE) score from baseline
Временное ограничение: Baseline, 3, 6, 12, 18, and 24 months
Cognitive function will be assessed using the Mini-Mental State Examination (MMSE; total score range 0-30, higher scores indicate better cognitive function). Changes in score from baseline will be evaluated at each follow-up visit.
Baseline, 3, 6, 12, 18, and 24 months
Change in modified Rankin Scale (mRS) score from baseline
Временное ограничение: Baseline, 3, 6, 12, 18, and 24 months
Functional neurological outcome will be assessed using the modified Rankin Scale (mRS; total score range 0-6, higher scores indicate greater disability). Changes from baseline will be analyzed.
Baseline, 3, 6, 12, 18, and 24 months
Change in NIH Stroke Scale (NIHSS) score from baseline
Временное ограничение: Baseline, 3, 6, 12, 18, and 24 months
Neurological deficit severity will be assessed using the National Institutes of Health Stroke Scale (NIHSS; total score range 0-42, higher scores indicate greater neurological deficit). Changes from baseline will be analyzed.
Baseline, 3, 6, 12, 18, and 24 months
Change in Stroke-Specific Quality of Life (SSQOL) score from baseline
Временное ограничение: Baseline, 3, 6, 12, 18, and 24 months
Quality of life will be assessed using the Stroke-Specific Quality of Life (SSQOL) scale (total score range 49-245, higher scores indicate better quality of life). Changes in SSQOL total score from baseline will be evaluated at each follow-up time point.
Baseline, 3, 6, 12, 18, and 24 months
Change in Barthel Index from baseline
Временное ограничение: Baseline, 3, 6, 12, 18, and 24 months
Activities of daily living will be assessed using the Barthel Index (total score range 0-100, higher scores indicate greater independence). Changes in Barthel Index score from baseline will be evaluated at each follow-up time point.
Baseline, 3, 6, 12, 18, and 24 months
Number of participants with recurrent stroke events
Временное ограничение: Up to 24 months
Recurrent stroke events include both ischemic and hemorrhagic stroke occurring after the index stroke. The number of participants experiencing at least one recurrent stroke will be recorded.
Up to 24 months
Number of participants with all-cause mortality
Временное ограничение: Up to 24 months
All-cause mortality will be defined as death from any cause occurring during the study period. The number of participants who die during follow-up will be recorded.
Up to 24 months
Change in tumor necrosis factor-alpha (TNF-α) levels from baseline
Временное ограничение: Baseline, 1 week, 1 month, 3 months, and 24 months
Serum TNF-α levels will be measured to assess inflammatory response. Changes from baseline at each time point will be analyzed.
Baseline, 1 week, 1 month, 3 months, and 24 months
Change in interleukin-1 beta (IL-1β) levels from baseline
Временное ограничение: Baseline, 1 week, 1 month, 3 months, and 24 months
Serum IL-1β levels will be measured as a marker of inflammation. Changes from baseline will be analyzed.
Baseline, 1 week, 1 month, 3 months, and 24 months
Change in cyclooxygenase-2 (COX-2) levels from baseline
Временное ограничение: Baseline, 1 week, 1 month, 3 months, and 24 months
COX-2 expression levels will be measured as part of inflammatory pathway assessment. Changes from baseline will be analyzed.
Baseline, 1 week, 1 month, 3 months, and 24 months
Change in inducible nitric oxide synthase (iNOS) levels from baseline
Временное ограничение: Baseline, 1 week, 1 month, 3 months, and 24 months
iNOS levels will be measured to evaluate inflammatory and oxidative stress responses. Changes from baseline will be analyzed.
Baseline, 1 week, 1 month, 3 months, and 24 months
Number of participants with treatment-emergent adverse events
Временное ограничение: Up to 24 months
Treatment-emergent adverse events (TEAEs) are defined as adverse events occurring after initiation of study treatment. The number of participants experiencing at least one TEAE will be recorded.
Up to 24 months
Number of participants with serious adverse events
Временное ограничение: Up to 24 months
Serious adverse events (SAEs) include events that result in death, are life-threatening, require hospitalization, or result in significant disability. The number of participants experiencing at least one SAE will be recorded.
Up to 24 months
Number of participants who discontinued treatment due to adverse events
Временное ограничение: Up to 24 months
Treatment discontinuation due to adverse events will be recorded as a measure of drug tolerability.
Up to 24 months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

First Affiliated Hospital of Wenzhou Medical University

Соавторы

Ningbo Medical Center Lihuili Hospital
The Central Hospital of Lishui City
Ningbo No.2 Hospital
The Third Affiliated Hospital of Wenzhou Medical University

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Общие публикации

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Оцененный)

1 июня 2026 г.

Первичное завершение (Оцененный)

1 июня 2030 г.

Завершение исследования (Оцененный)

1 декабря 2030 г.

Даты регистрации исследования

Первый отправленный

14 сентября 2025 г.

Впервые представлено, что соответствует критериям контроля качества

20 мая 2026 г.

Первый опубликованный (Действительный)

22 мая 2026 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

22 мая 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

20 мая 2026 г.

Последняя проверка

1 мая 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Ключевые слова

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • KY2025-328-02 (Другой идентификатор: Ethics Committee in Clinical Research (ECCR) of the First Affiliated Hospital of Wenzhou Medical University)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Описание плана IPD

De-identified individual participant data (IPD) will not be publicly shared due to privacy and ethical considerations. However, data may be made available to qualified researchers upon reasonable request, subject to institutional review and data sharing agreements.

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться